Review

Cancer Immunology, Immunotherapy

, Volume 56, Issue 4, pp 429-445

First online:

Vaccination therapy in prostate cancer

  • Andrea MarrariAffiliated withUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori Email author 
  • , Manuela IeroAffiliated withUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Lorenzo PillaAffiliated withUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Sergio VillaAffiliated withUnit of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Roberto SalvioniAffiliated withUrology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Riccardo ValdagniAffiliated withProstate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Giorgio ParmianiAffiliated withUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori
  • , Licia RivoltiniAffiliated withUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Radical prostatectomy and radiation therapy provide excellent localized prostate cancer (PC) control. Although the majority of prostate carcinoma is nowadays diagnosed at early stages with favourable risk features, in patients up to 30–40% it recurs within 10 years. Furthermore, the lack of effective therapies, once prostate carcinoma becomes refractory to androgen deprivation, mandates the development of alternative therapeutic options. There is a growing interest in harnessing the potency and specificity of anti-tumour immunity through the generation of fully competent dendritic cells and tumour reactive effector lymphocytes. Several strategies to treat or prevent the development of metastatic PC have been explored in clinical trials and are summarized in this review, considering also the feasibility and safety of these approaches. In some cases clinical responses were achieved showing that vaccine-primed T cells induced anti-tumour activity in vivo. The present findings and perspectives of the immunologic interventions in PC patients will be discussed.

Keywords

Prostate cancer Antigens Cancer vaccine Tumour immunity Androgen deprivation therapy Radiotherapy